Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
ArmaGen Technologies, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'ArmaGen Technologies, Inc. - Product Pipeline Review - 2014', provides an overview of the ArmaGen Technologies, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of ArmaGen Technologies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of ArmaGen Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of ArmaGen Technologies, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the ArmaGen Technologies, Inc.'s pipeline products Reasons to buy - Evaluate ArmaGen Technologies, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of ArmaGen Technologies, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the ArmaGen Technologies, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of ArmaGen Technologies, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of ArmaGen Technologies, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of ArmaGen Technologies, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 ArmaGen Technologies, Inc. Snapshot 5 ArmaGen Technologies, Inc. Overview 5 Key Information 5 Key Facts 5 ArmaGen Technologies, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 ArmaGen Technologies, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 ArmaGen Technologies, Inc. - Pipeline Products Glance 10 ArmaGen Technologies, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 ArmaGen Technologies, Inc. - Drug Profiles 12 AGT-110 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 AGT-115 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AGT-160 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 AGT-181 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AGT-182 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AGT-183 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AGT-190 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AGT-184 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ArmaGen Technologies, Inc. - Pipeline Analysis 21 ArmaGen Technologies, Inc. - Pipeline Products by Target 21 ArmaGen Technologies, Inc. - Pipeline Products by Route of Administration 22 ArmaGen Technologies, Inc. - Pipeline Products by Molecule Type 23 ArmaGen Technologies, Inc. - Pipeline Products by Mechanism of Action 24 ArmaGen Technologies, Inc. - Recent Pipeline Updates 25 ArmaGen Technologies, Inc. - Dormant Projects 27 ArmaGen Technologies, Inc. - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables ArmaGen Technologies, Inc., Key Information 5 ArmaGen Technologies, Inc., Key Facts 5 ArmaGen Technologies, Inc. - Pipeline by Indication, 2014 7 ArmaGen Technologies, Inc. - Pipeline by Stage of Development, 2014 8 ArmaGen Technologies, Inc. - Monotherapy Products in Pipeline, 2014 9 ArmaGen Technologies, Inc. - Preclinical, 2014 10 ArmaGen Technologies, Inc. - Discovery, 2014 11 ArmaGen Technologies, Inc. - Pipeline by Target, 2014 21 ArmaGen Technologies, Inc. - Pipeline by Route of Administration, 2014 22 ArmaGen Technologies, Inc. - Pipeline by Molecule Type, 2014 23 ArmaGen Technologies, Inc. - Pipeline Products by Mechanism of Action, 2014 24 ArmaGen Technologies, Inc. - Recent Pipeline Updates, 2014 25 ArmaGen Technologies, Inc. - Dormant Developmental Projects,2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.